Inhaled Mebufotenine Shows Promise for Treatment-Resistant Depression
A phase 2 clinical trial published in JAMA Psychiatry on March 25, 2026, indicates that inhaled mebufotenine may significantly improve symptoms of treatment-resistant depression. The study, with participation from Spanish researchers, suggests a potential new, fast-acting treatment option for individuals who haven’t responded to traditional antidepressants.
How Mebufotenine Works
Mebufotenine (also known as 5-MeO-DMT) is a psychoactive molecule that, when inhaled, produces peak effects within minutes, with a duration of less than an hour. The trial investigated its efficacy in patients with treatment-resistant depression – those who have not responded to two or more antidepressant medications.
Study Findings
The randomized, controlled clinical trial involved 40 patients receiving mebufotenine and 41 receiving a placebo. Results demonstrated a substantial improvement in the treatment group, with a greater than 15-point reduction on a 60-point depression scale compared to the placebo group, as early as two hours after administration. This effect was sustained one week later.
Notably, nearly 60% of patients in the mebufotenine group achieved remission of depression symptoms (minimal symptoms), compared to 0% in the placebo group. Researchers reported that adverse effects were mild to moderate and transient, with no serious adverse events observed.
Key Considerations and Limitations
While promising, the use of inhaled mebufotenine is not without limitations:
- Administration & Supervision: Mebufotenine requires inhalation and must be administered under professional supervision due to its psychedelic effects. Prior preparation and monitoring are essential.
- Antidepressant Discontinuation: Study participants were required to discontinue antidepressant treatment for at least two weeks prior to the trial, which could have led to temporary worsening of symptoms and potentially amplified the observed treatment effect.
- Long-Term Effects: While the initial response lasts for one week, medium- to long-term follow-up (six months) showed depressive relapses in some patients. However, re-administration of mebufotenine led to remission in 87% of those cases (results to be published separately).
- Blinding Challenges: The psychedelic effects of mebufotenine made it tricky to maintain a true placebo-controlled environment, as participants could likely discern whether they received the active treatment.
- Selection Bias: Participants aware of the possibility of receiving a psychedelic substance may have experienced an expectation bias, potentially influencing the results.
Expert Perspective
Dr. Gerard Anmella, a psychiatrist and researcher at the Unit for Depressive and Bipolar Disorders at Hospital Clínic in Barcelona, highlighted the study’s significance: “This is an effective, rapid treatment with no serious adverse effects. It has a profile clearly distinct from that of classic antidepressants: rapid onset, no need for daily administration, and efficacy within hours rather than weeks.” He also noted that psychotherapy could potentially enhance the treatment’s effectiveness.
Future Directions
The research suggests that psychedelics represent a promising therapeutic avenue for treatment-resistant depression. Further investigation is needed to optimize treatment protocols, understand long-term effects, and explore the potential benefits of combining mebufotenine with psychotherapy.
Study Citation: Cubała, W. J. et al. ‘GH001 vs Placebo in Patients With Treatment-Resistant Depression A Randomized Clinical Trial’. JAMA Psychiatry, Published online March 25, 2026. DOI: 10.1001/jamapsychiatry.2026.0096
Source: Science Media Centre Spain
Keep reading